Mannkind (MNKD) Depreciation & Amortization (CF) (2010 - 2026)
Mannkind (MNKD) posted quarterly Depreciation & Amortization (CF) of $6.4 million for Q1 2026, up 203.04% year-over-year from $2.1 million in Q1 2025, and up 5.84% quarter-over-quarter from $6.0 million in Q4 2025.
Mannkind (MNKD) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $6.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 203.04% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $16.6 million (up 104.04% YoY), while the FY2025 annual figure was $12.3 million, up 66.65% from the prior year.
- Depreciation & Amortization (CF) advanced to $6.4 million in Q1 2026 per MNKD's latest filing, from $6.0 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $6.4 million in Q1 2026 and bottomed at $599000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $2.0 million across 5 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slipped 28.44% — and 2026, when it soared 203.04%.
- Mannkind's Depreciation & Amortization (CF) stood at $1.0 million in 2022, then climbed by 20.45% to $1.2 million in 2023, then jumped by 76.33% to $2.2 million in 2024, then jumped by 179.17% to $6.0 million in 2025, then climbed by 5.84% to $6.4 million in 2026.
- Business Quant data shows MNKD's Depreciation & Amortization (CF) at $6.4 million in Q1 2026, $6.0 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 6.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.40 Mn |
| Jun 30, 2026 | 6.40 Mn |
| Mar 31, 2026 | 6.38 Mn |
| Mar 31, 2026 | 6.38 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.12 Mn |
| Sep 30, 2024 | 2.12 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |